Mirikizumab

Mirikizumab (INN;[1] development code LY3074828) is a human monoclonal antibody designed for the treatment of psoriasis.

Mirikizumab
Monoclonal antibody
Type?
SourceHumanized (from mouse)
Targetinterleukin 23A
Clinical data
Other namesLY3074828
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6380H9842N1686O2004S48
Molar mass143767.59 g·mol−1

This drug was developed by Eli Lilly and Co.[2] As of 2018, mirikizumab is undergoing Phase III trials.

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.